ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

National Cancer Centre Singapore at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

National Cancer Centre Singapore takes part in 15 sessions at ESMO 2026 in Madrid. Its program covers treatment and outcomes across breast, lung and other cancers, alongside cancer testing and supportive care. Topics include breast cancer recurrence patterns and how radiation treatment is planned for nasopharyngeal cancer.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Public specialist cancer centre in Singapore, part of the SingHealth public healthcare cluster.
Satellite
Fri Oct 23
10:40–11:05
Across the TNBC Spectrum: Therapeutic Innovation With ADCs
Medscape Global Oncology - Redrawing the Breast Cancer Roadmap: Advancing Novel Therapies Into First-Line and Early Disease Settings
Breast cancer
Poster
Fri Oct 23
13:00–15:00
Evaluating the prognostic utility of a genomic classifier (GC) in an Asian real-world cohort of localized prostate cancer (PCa)
ePoster session 11
Genitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
15:15–16:00
Deriving mechanism of action for BiTEs using a phase 0.9 preclinical platform
Friday Poster Display session 2
Sarcoma, CNS, head & neck and rare cancers
Chair
Sat Oct 24
08:30–10:00
Rapid oral: Investigational immunotherapy
with University of Fribourg, Memorial Sloan Kettering Cancer Center
Abstract
Sat Oct 24
08:45–09:00
Invited Discussant 1950RO, 1955RO and LBA52
Rapid oral: Investigational immunotherapy
Poster
Sat Oct 24
12:00–12:45
Validation of LIFE: An adolescent and young adult with cancer (AYAO) - Specific rapid distress screening tool
Saturday Poster Display session 5
Nursing & supportive care
Chair
Sun Oct 25
08:30–10:00
All about cancer vaccines
with University Hospital Tübingen
Chair
Sun Oct 25
10:15–11:30
Evolving treatment paradigms in nasopharyngeal carcinoma
with Catalan Institute of Oncology (ICO)
Sarcoma, CNS, head & neck and rare cancers
Talk
Sun Oct 25
10:40–11:00
The role of radiation oncologist
Evolving treatment paradigms in nasopharyngeal carcinoma
Sarcoma, CNS, head & neck and rare cancers
Chair
Mon Oct 26
08:30–09:15
Chair
Mon Oct 26
10:15–11:00
Poster
Mon Oct 26
12:00–12:45
Poster
Mon Oct 26
12:00–12:45
Talk
Mon Oct 26
17:10–17:30
Peri-operative strategies in oncogene driven resectable early stage NSCLC
Resectable early stage NSCLC
Lung & thoracic cancers
Satellite
Mon Oct 26
19:20–19:40
How I Test, How I Think, How I Treat: Clinical Evidence, Best Practices, and Hot Seat Challenges, Part 3: Assessing the Evidence and Finessing the Therapeutic Formula in HER2-Altered NSCLC
PeerView Oncology - Leveraging HER2-Targeted ADCs in Solid Tumours: Expert Strategies for Advancing Biomarker Testing, Decoding Data, and Closing Treatment Gaps
Biomarkers & precision oncology
Satellite
Mon Oct 26
19:40–20:00
Open Discussion Forum, Q&A and Key Takeaways: Optimizing Treatment With HER2- Directed ADCs to Close Treatment Gaps in Solid Tumours
PeerView Oncology - Leveraging HER2-Targeted ADCs in Solid Tumours: Expert Strategies for Advancing Biomarker Testing, Decoding Data, and Closing Treatment Gaps · with Fred & Pamela Buffett Cancer Center, University Hospitals Leuven
Biomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at National Cancer Centre Singapore

Tell us what you sell and we’ll find the people at National Cancer Centre Singapore most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction